LB PHARMACEUTICALS INC(LBRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
LBRX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for LB PHARMACEUTICALS INC (LBRX), a Healthcare sector company. LBRX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), LB PHARMACEUTICALS INC reports net income of $-19.1M, free cash flow of $-23.3M. Top institutional holders of LBRX by reported 13-F value include Deep Track Capital,, BlackRock,, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. LBRX trades on the Nasdaq exchange and files with the SEC under CIK 1691082. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LB PHARMACEUTICALS INC directly from SEC EDGAR.
Net Income
Q1 2026
$-19.1M
Free Cash Flow
Q1 2026
$-23.3M
ROIC
Q1 2026
-5.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+60.1% YoYEPS (Diluted)
+98.2% YoYTotal Assets
+833.2% YoYOp. Cash Flow
+33.6% YoY| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Net Income | $-25.2M +60.1% | $-63.1M |
| EPS (Diluted) | $-3.13 +98.2% | $-176.15 |
| Total Assets | $312.9M +833.2% | $33.5M |
| Operating Cash Flow | $-35.2M +33.6% | $-53.1M |
AI Insight: LBRX Financial Trends
LBRX burning cash and equity capital with no revenue visibility across three quarters.
• Operating cash flow negative and worsening: −$18M in Q4 2025, −$23M in Q1 2026.
• Net losses accelerating: −$11M in Q4 2025 to −$19M in Q1 2026.
• Equity declined from $310M (Q3 2025) to $301M (Q4 2025), then rose to $379M (Q1 2026).
⚠ No revenue reported across all three quarters—product launch status or commercial execution unclear.
⚠ Cash burn rate accelerating; Q1 2026 operating cash outflow highest on record.
AI Insight: LBRX Ratio Trends
LBRX swung to deeper losses in Q1 2026, with ROE deteriorating to -20.1% from -15.2% in Q4 2025.
• ROE declined 4.9 percentage points quarter-over-quarter to -20.1% in Q1 2026, signaling accelerating shareholder value destruction.
• ROA mirrored ROE weakness, falling to -19.4% in Q1 2026 from -14.7% in Q4 2025, indicating asset base is not generating returns.
⚠ Operating and net profit margins unavailable; cannot assess operational performance or underlying profitability drivers.
⚠ Debt-to-equity ratio absent from all periods; leverage trajectory and financial structure unknown amid mounting losses.
Get alerted when LBRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for LB PHARMACEUTICALS INC including:
Top Institutional Holders of LBRX
Deep Track Capital, LP
$82.7M3,352,804 shBlackRock, Inc.
$60.9M2,470,845 shRA CAPITAL MANAGEMENT, L.P.
$54.5M2,208,604 shTCG Crossover Management, LLC
$45.3M1,839,489 shCommodore Capital LP
$37.0M1,500,000 shCaligan Partners LP
$34.6M1,438,070 shSpruce Street Capital LP
$33.6M1,376,159 shTrails Edge Capital Partners, LP
$32.5M1,319,362 shNantahala Capital Management, LLC
$26.0M1,052,894 shBALYASNY ASSET MANAGEMENT L.P.
$22.8M923,694 sh
| Fund | Value | Shares |
|---|---|---|
| Deep Track Capital, LP | $82.7M | 3,352,804 |
| BlackRock, Inc. | $60.9M | 2,470,845 |
| RA CAPITAL MANAGEMENT, L.P. | $54.5M | 2,208,604 |
| TCG Crossover Management, LLC | $45.3M | 1,839,489 |
| Commodore Capital LP | $37.0M | 1,500,000 |
| Caligan Partners LP | $34.6M | 1,438,070 |
| Spruce Street Capital LP | $33.6M | 1,376,159 |
| Trails Edge Capital Partners, LP | $32.5M | 1,319,362 |
| Nantahala Capital Management, LLC | $26.0M | 1,052,894 |
| BALYASNY ASSET MANAGEMENT L.P. | $22.8M | 923,694 |
More Healthcare Companies
View all Healthcare →Put LBRX on your watchlist
Track score changes the day LB PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LBRX a good stock to buy?
13F Pro's AI-powered analysis of LB PHARMACEUTICALS INC (LBRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LBRX are available on the LBRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own LBRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LBRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LB PHARMACEUTICALS INC's investment landscape.